Tuesday, January 09, 2018 10:15 PM ET
Insider Selling in CRISPR Therapeutics (CRSP) Shares Continues
A filing with the SEC today disclosed a significant insider sale of CRISPR Therapeutics shares as — Kurt von Emster, Director — disposed of 92,337 shares in the company having a market value of approximately $2,489,406. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 1,212,882 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 1,305,219 shares and have averaged 217,537 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at CRISPR Therapeutics is greater than its 191-company peer group average. The Biotechnology & Medical Research peer group saw 163 buy/sell trades during this period for an average of 0.9 transactions per company. However, the number of shares traded per transaction by CRISPR Therapeutics insiders is lower than its peers. Within the peer group there were 26,485,061 shares purchased and 11,532,056 shares sold with company insiders purchasing 123,579 shares on average over this time period.
To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data obtained to create and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.